[en] Purpose of review Allogeneic hematopoietic cell transplantation with myeloablative conditioning is a well established therapy for patients with acute myeloid leukemia. Its efficacy depends, in part, on the destruction of recipient acute myeloid leukemia cells by the conditioning regimen and, in part on their removal by donor immune cells contained in the graft (graft-versus-tumor effect). Due to regiment related toxicities, the use of myeloablative allogeneic hematopoietic cell transplantation has been restricted to younger patients in good condition. More recently, the introduction of allogeneic hematopoietic cell transplantation following reduced-intensity or nonmyeloablative conditioning regimens, which rely mainly on graft-versus-tumor effects for tumor cell eradication, has permitted extending hematopoietic cell transplantation to include older patients and those with medical comorbidities. Recent findings Early results with allogeneic hematopoietic cell transplantation after nonmyeloablative and reduced-intensity conditioning for patients with acute myeloid leukemia in first complete remission are encouraging, with 2-year survivals after hematopoietic cell transplantation ranging from 48 to 79% among studies. Further, retrospective studies have demonstrated similar outcomes in adult patients with acute myeloid leukemia in complete remission given either myeloablative or nonmyeloablative conditioning. Summary Prospective studies are needed to define the place of allogeneic hematopoietic cell transplantation after nonmyeloablative or reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission, and to determine a role for consolidation chemotherapy before hematopoietic cell transplantation, if any.
Disciplines :
Hématologie
Auteur, co-auteur :
Baron, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie
Storb, R.
Langue du document :
Anglais
Titre :
Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission
Date de publication/diffusion :
mars 2007
Titre du périodique :
Current Opinion in Hematology
ISSN :
1065-6251
eISSN :
1531-7048
Maison d'édition :
Lippincott Williams & Wilkins, Philadelphia, Etats-Unis - Pennsylvanie
Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002; 100:3869-3876.
Cancer and Leukemia Group, Farag SS, Archer KJ, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 84K61. Blood 2006; 108:63-73.
Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481-3485.
Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332:217-223.
Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102:1232-1240.
Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versushost disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300:1068-1073.
Kolb HJ, Schmidt C, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103:767-776.
Appelbaum FR, Pearce SF. Hematopoietic cell transplantation in first complete remission versus early relapse. Baillieres Best Pract Res Clin Haematol 2006; 19:333-339.
de Labarthe A, Pautas C, Thomas X, et al. Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with goodrisk acute myeloid leukemia. Bone Marrow Transplant 2005; 35:767-773.
Baron F, Sandmaier BM. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol 2005; 12:435-443.
Baron F, Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (Review). Molecular Therapy 2006; 13:26-41.
Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20:1661-1672.
Lazarus HM, Rowe JM. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct? Leukemia 2006; 20:1673-1682. This paper discusses the role of reduced-intensity conditioning in patients with AML.
de Lima M, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome (Review). Semin Hematol 2006; 43:107-117. This paper discusses the role of reduced-intensity conditioning in patients with AML or myelodysplastic syndromes.
Baron F, Storb R, Storer BE, et al. Allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning after failed myeloablative HCT. J Clin Oncol 2006; 24:4150-4157.
McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97:3390-3400.
Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104:2254-2262.
de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reducedintensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:865-872.
Maris MB, Sandmaier BM, Storer BE, et al. Unrelated donor granulocyte colonystimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006; 12:454-465.
Sayer HG, Kröger M, Beyer J, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31:1089-1095.
Hallemeier C, Girgis M, Blum W, et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 2004; 10:310-319.
Blaise DP, Boiron JM, Faucher C, et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104:1931-1938. This study showed encouraging results for patients with AML in first complete remission given grafts from HLA-identical sibling donors after conditioning with busulfan, fludarabine and ATG. Interestingly, occurrence of chronic GVHD was associated with lower risks of relapse and better progression-free survival.
Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with highrisk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23:9387-9393. This large multicenter study showed encouraging survival and low incidences of GVHD and nonrelapse mortality in patients given alemtuzumab-containing reduced-intensity conditioning.
Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24:444-453. This large multicenter study (n = 122) showed encouraging results for patients with AML in complete remission after conditioning with 2 Gy TBI with or without added fludarabine. Interestingly, results with HLA-matched unrelated donors were at least as good as those obtained with HLA-identical siblings.
Mohty M, de Lavallade H, Ladaique P, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005; 19:916-920. This is the first intention-to-treat study demonstrating that allogeneicHCT following reduced-intensity conditioning improved survival in comparison with chemotherapy alone.
van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23:5728-5738.
Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23:1993-2003.
Baron F, Maris MB, Storer BE, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2005; 11:272-279.
Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006; 20:1690-1700.
Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20:128-135. This single-center study showed comparable survival in patients with myelodysplastic syndromes given allogeneic grafts following either myeloablative or nonmyeloablative conditioning.
Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19:2304-2312. This multicenter study showed comparable survivals in patients with AML receiving allogeneic grafts following either myeloablative or nonmyeloablative conditioning.
Deeg HJ, Maris MB, Scott BL, et al. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia 2006; 20:1701-1705.
Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912-2919. The authors describe how the use of the HCT-CI might help decide which patients may most benefit from myeloablative or nonmyeloablative conditioning.
Sorror M, Storer B, Sandmaier BM, et al. Relationship between conditioning intensity and comorbidity in patients (pts) with acute myeloid leukemia (AML) or myelodysplasia (MDS) receiving allogeneic hematopoietic cell transplantation [abstract]. Blood 2005; 106 (art 1):208a.
Cahn JY, Labopin M, Sierra J, et al. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 308-314.
Tallman MS, Rowlings PA, Milone G, et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000; 96:1254-1258.
Panse JP, Heimfeld S, Guthrie KA, et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after nonmyeloablative conditioning. Br J Haematol 2005; 128:659-667.
Baron F, Storer B, Maris MB, et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12:1176-1187.
Baron F, Maris MB, Storer BE, et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005; 19:822-828.
Gorin NC, Labopin M, Boiron JM, et al. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond-the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2006; 24:3959-3966.
Pagel JM, Appelbaum FR, Sandmaier BM, et al. 131I-anti- CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) [abstract]. Blood 2005; 106 (Part 1):119a.
